Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database

Background: Glioblastoma (GBM) is the most common primary intracranial malignancy. Previous studies found incidence of GBM varies substantially by age, sex, race and ethnicity, and survival also varies by country, ethnicity, and treatment. Gliosarcoma (GSM) and giant cell glioblastoma (GC-GBM) are d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Li-Tsun Shieh, Chung-Han Ho, How-Ran Guo, Chien-Cheng Huang, Yi-Chia Ho, Sheng-Yow Ho
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/65b20fc09c354a168ca63446b3744603
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:65b20fc09c354a168ca63446b3744603
record_format dspace
spelling oai:doaj.org-article:65b20fc09c354a168ca63446b37446032021-11-30T15:36:24ZEpidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database1664-229510.3389/fneur.2021.659921https://doaj.org/article/65b20fc09c354a168ca63446b37446032021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fneur.2021.659921/fullhttps://doaj.org/toc/1664-2295Background: Glioblastoma (GBM) is the most common primary intracranial malignancy. Previous studies found incidence of GBM varies substantially by age, sex, race and ethnicity, and survival also varies by country, ethnicity, and treatment. Gliosarcoma (GSM) and giant cell glioblastoma (GC-GBM) are different histologic variants of GBM with distinct clinico-pathologic entities. We conducted a study to compare epidemiology, survival, and prognostic factors among the three.Methods: We identified GBM patients diagnosed between 2000 and 2016 using the Taiwan Cancer Registry and followed them using the death registry. Survival was compared among conventional GBM and two histologic variants. The potential confounding factors evaluated in this study included registered year, age, sex, and treatment modality (resection, radiotherapy, and chemotherapy).Results: We enrolled 3,895 patients, including 3,732 (95.8%) with conventional GBM, 102 (2.6%) with GSM, and 61 (1.6%) with GC-GBM. GC-GBM patients had younger mean age at diagnosis (49.5 years) than conventional GBM patients (58.7 years) and GSM patients (61.3 years) (p < 0.01). The three groups had similar sex distributions (p = 0.29). GC-GBM had a longer median survival [18.5, 95% confidence interval (CI): 15.8–25.3 months] than conventional GBM (12.5, 95%CI: 12.0–13.0 months) and GSM (12.8, 95%CI: 9.2–16.2 months), and the differences in overall survival did not attain statistical significance (p = 0.08, log-rank test). In univariate analysis, GC-GBM had better survival than conventional GBM, but the hazard ratio (0.91) did not reach statistical significance (95%CI: 0.69–1.20) in the multivariate analysis. Young ages (≤ 40 years), female sex, resection, radiotherapy, and chemotherapy were factors associated with better survival in overall GBMs. In subtype analyses, these factors remained statistically significant for conventional GBM, as well as radiotherapy for GSM.Conclusion: Our analysis found conventional GBM and its variants shared similar poor survival. Factors with age ≤ 40 years, female sex, resection, radiotherapy, and chemotherapy were associated with better prognosis in conventional GBM patients.Li-Tsun ShiehChung-Han HoChung-Han HoHow-Ran GuoHow-Ran GuoChien-Cheng HuangChien-Cheng HuangYi-Chia HoSheng-Yow HoSheng-Yow HoSheng-Yow HoFrontiers Media S.A.articleglioblastomagliosarcomagiant cell glioblastomahistologic variantepidemiologyNeurology. Diseases of the nervous systemRC346-429ENFrontiers in Neurology, Vol 12 (2021)
institution DOAJ
collection DOAJ
language EN
topic glioblastoma
gliosarcoma
giant cell glioblastoma
histologic variant
epidemiology
Neurology. Diseases of the nervous system
RC346-429
spellingShingle glioblastoma
gliosarcoma
giant cell glioblastoma
histologic variant
epidemiology
Neurology. Diseases of the nervous system
RC346-429
Li-Tsun Shieh
Chung-Han Ho
Chung-Han Ho
How-Ran Guo
How-Ran Guo
Chien-Cheng Huang
Chien-Cheng Huang
Yi-Chia Ho
Sheng-Yow Ho
Sheng-Yow Ho
Sheng-Yow Ho
Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
description Background: Glioblastoma (GBM) is the most common primary intracranial malignancy. Previous studies found incidence of GBM varies substantially by age, sex, race and ethnicity, and survival also varies by country, ethnicity, and treatment. Gliosarcoma (GSM) and giant cell glioblastoma (GC-GBM) are different histologic variants of GBM with distinct clinico-pathologic entities. We conducted a study to compare epidemiology, survival, and prognostic factors among the three.Methods: We identified GBM patients diagnosed between 2000 and 2016 using the Taiwan Cancer Registry and followed them using the death registry. Survival was compared among conventional GBM and two histologic variants. The potential confounding factors evaluated in this study included registered year, age, sex, and treatment modality (resection, radiotherapy, and chemotherapy).Results: We enrolled 3,895 patients, including 3,732 (95.8%) with conventional GBM, 102 (2.6%) with GSM, and 61 (1.6%) with GC-GBM. GC-GBM patients had younger mean age at diagnosis (49.5 years) than conventional GBM patients (58.7 years) and GSM patients (61.3 years) (p < 0.01). The three groups had similar sex distributions (p = 0.29). GC-GBM had a longer median survival [18.5, 95% confidence interval (CI): 15.8–25.3 months] than conventional GBM (12.5, 95%CI: 12.0–13.0 months) and GSM (12.8, 95%CI: 9.2–16.2 months), and the differences in overall survival did not attain statistical significance (p = 0.08, log-rank test). In univariate analysis, GC-GBM had better survival than conventional GBM, but the hazard ratio (0.91) did not reach statistical significance (95%CI: 0.69–1.20) in the multivariate analysis. Young ages (≤ 40 years), female sex, resection, radiotherapy, and chemotherapy were factors associated with better survival in overall GBMs. In subtype analyses, these factors remained statistically significant for conventional GBM, as well as radiotherapy for GSM.Conclusion: Our analysis found conventional GBM and its variants shared similar poor survival. Factors with age ≤ 40 years, female sex, resection, radiotherapy, and chemotherapy were associated with better prognosis in conventional GBM patients.
format article
author Li-Tsun Shieh
Chung-Han Ho
Chung-Han Ho
How-Ran Guo
How-Ran Guo
Chien-Cheng Huang
Chien-Cheng Huang
Yi-Chia Ho
Sheng-Yow Ho
Sheng-Yow Ho
Sheng-Yow Ho
author_facet Li-Tsun Shieh
Chung-Han Ho
Chung-Han Ho
How-Ran Guo
How-Ran Guo
Chien-Cheng Huang
Chien-Cheng Huang
Yi-Chia Ho
Sheng-Yow Ho
Sheng-Yow Ho
Sheng-Yow Ho
author_sort Li-Tsun Shieh
title Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
title_short Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
title_full Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
title_fullStr Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
title_full_unstemmed Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
title_sort epidemiologic features, survival, and prognostic factors among patients with different histologic variants of glioblastoma: analysis of a nationwide database
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/65b20fc09c354a168ca63446b3744603
work_keys_str_mv AT litsunshieh epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT chunghanho epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT chunghanho epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT howranguo epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT howranguo epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT chienchenghuang epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT chienchenghuang epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT yichiaho epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT shengyowho epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT shengyowho epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
AT shengyowho epidemiologicfeaturessurvivalandprognosticfactorsamongpatientswithdifferenthistologicvariantsofglioblastomaanalysisofanationwidedatabase
_version_ 1718406508721471488